Venkat Pavan Kancharla, MD
Medical Oncology · Palm Bay, FLNPI 1205091758
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 13.0%. 2025 is the largest year on record at $30,766, 2.5 times the $12,390 reported in 2019. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,762 payments — averaging $52.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Jazz Pharmaceuticals Inc.$10K
- Johnson & Johnson$7K
- Bayer$6K
- Novartis$5K
- Pfizer$4K
- plus $45K from 54 others
Across 427 payments — averaging $3176.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$466K
- Genentech, Inc.$416K
- AstraZeneca$169K
- Daiichi Sankyo Inc.$142K
- Pfizer$75K
- Sanofi US Services Inc.$46K
- plus $43K from 8 others
What the payments were for
- Consulting fees$22,93825%
- Speaking & faculty fees$10,87712%
- Travel & lodging$2,4903%
- Food & beverage$51,54856%
- Education$1,2621%
- Gifts$1,9652%
- Other$1,0151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,096 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 70 | $1,192,626 |
| Lenalidomide | 65 | $751,305 |
| QinlockRipretinib | 11 | $458,725 |
| PomalystPomalidomide | 20 | $445,125 |
| JakafiRuxolitinib Phosphate | 25 | $429,782 |
| KisqaliRibociclib Succinate | 25 | $419,577 |
| ImbruvicaIbrutinib | 22 | $340,277 |
| CalquenceAcalabrutinib Maleate | 25 | $339,565 |
| TagrissoOsimertinib Mesylate | 18 | $302,902 |
| ErleadaApalutamide | 20 | $263,148 |
| SprycelDasatinib | 13 | $223,206 |
| BrukinsaZanubrutinib | 12 | $181,525 |
| VenclextaVenetoclax | 12 | $174,507 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $154,566 |
| Abiraterone Acetate | 31 | $114,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,342 | $1,192,62670 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $3,943 | $668,33133 claims |
| AstraZenecaCalquence, Tagrisso | $11,999 | $642,46743 claims |
| Deciphera Pharmaceuticals Inc.Qinlock | $100 | $458,72511 claims |
| Incyte CorporationJakafi | $2,258 | $429,78225 claims |
| NovartisKisqali | $5,369 | $419,57725 claims |
| Johnson & JohnsonErleada, Xarelto, Procrit | $7,238 | $371,627109 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $518 | $340,27722 claims |
| AbbVieVenclexta, Creon | $908 | $199,40538 claims |
| Beigene USA, Inc.Brukinsa | $2,836 | $181,52512 claims |
| Taiho Oncology, Inc.Lonsurf | $338 | $154,56612 claims |
| PfizerEliquis, Retacrit | $4,092 | $101,957134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Palm Bay
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.